Cargando…
Defects of CTLA-4 Are Associated with Regulatory T Cells in Myasthenia Gravis Implicated by Intravenous Immunoglobulin Therapy
Myasthenia gravis (MG) is a CD4(+) T cell-dependent autoimmune disease resulting from aberrant immune response mediated by circulating autoantibodies at the neuromuscular junction. Intravenous immunoglobulin (IVIg) is an expensive and commonly used immunotherapeutic approach to treat patients with M...
Autores principales: | Xu, Wenhua, Ren, Mingshan, Ghosh, Swagata, Qian, Kai, Luo, Zhaofeng, Zhang, Aimei, Zhang, Cuiping, Cui, Jiajun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042523/ https://www.ncbi.nlm.nih.gov/pubmed/32148437 http://dx.doi.org/10.1155/2020/3645157 |
Ejemplares similares
-
Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis
por: Díez-Porras, Laura, et al.
Publicado: (2020) -
Coronary spastic angina after the administration of intravenous immunoglobulin in myasthenia gravis: a case report
por: Yanagihashi, Masaru, et al.
Publicado: (2020) -
CTLA-4 methylation regulates the pathogenesis of myasthenia gravis and the expression of related cytokines
por: Fang, Ti-Kun, et al.
Publicado: (2018) -
Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis
por: Blaha, M., et al.
Publicado: (2010) -
CTLA4 Variants and Haplotype Contribute Genetic Susceptibility to Myasthenia Gravis in Northern Chinese Population
por: Sun, Liang, et al.
Publicado: (2014)